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of Blumea balsamifera DC leaves measured using the P-carotene-
linoleic acid model system. BHT was used as reference compoWld. 
Hydrogen donating ability of 1 mg/mL (final concentration of 
antioxidant in the reaction medium is 200 j.J.g) of different solvent 
extracts [Pet-ether (PEB), Chlorofonn (CEB) and Methanol (MEB)] 
of Blumea balsamifera DC leaves measured using the P-carotene-
linoleic acid model system. BHT was used as reference compound. 
Hydrogen donating ability of tlavonoids (5.2 X 1 o·S l'vi) of Blumea 
balsamifera DC. BHT was used as reference compounds. (+) 
rhamnetin (BL-IX); (D) BHT; (A.) quercetin (BL-XII); (x) blumeatin 
(BL-VI); (*) dihydroquercetin-4',7-dimethyl ether (BL-V); (e) 
control. 
Hydrogen donating ability (5.2 X 1 o·S M) of Blumea balsamifera DC. 
BHA and a-tocopherol were used as reference compounds. (+) 
Tamarixetin (BL-VIII); (*) luteolin (BL-XI); (..&.) BHA; (6) a-
tocopherol; (x) 5,7,3',5'-tetrahydroxyflavanone (BL-XIII); (D) 
dihydroquercetin-4'-methyl ether (BL-XIV); (e) controL 
Free radical scavenging activity of different solvent extracts [Pet-
ether (PEB), Chloroform (CEB) and Methanol (MEB)] of Blumea 
balsamifera DC leaves measured using the DPPH-assay. Results are 
mean ± S.D. (n = 3). a-Tocopherol (TOC) was used as reference 
compound. 
Hydrogen donating abilities of different concentration of 
dihydroquercetin-7 ,4' -dimethyl ether (BL-V) and dihydroquercetin-
4'-methyl ether (BL-XIV) found in Blumea balsamifera DC leaves 
on 1, 1-diphenyl-2-picrylhydrazyl (DPPH) radical. 
Hydrogen donating abilities of different concentration of tamarixetin 
(BL-VIII) and rhamnetin (BL-IX) found in Blumea balsamifera DC 
leaves and L-ascorbic acid (AA), on 1,1-diphenyl-2-picrylhydrazyl 
(DPPH) radical. AA was used as reference compound. 
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Hydrogen donating abilities of different concentration of luteolin-7-
methyl ether (BL-X) and luteolin (XI) found in Blumea balsamifera 
DC leaves and a-tocopherol, on 1,1-diphenyl-2-picrylhydrazyl 
(DPPH) radical. a-Tocopherol was used as reference compound. 
Hydrogen donating abilities of different concentration of quercetin 
(BL-XII) found in Blumea balsamifera DC leaves and butyla!ed 
hydroxytoluene (BHT), on 1,1-diphenyl-2-picrylhydrazyl (DPPH) 
radical. BHT was used as reference compound. 
Hydrogen donating ability of different concentration of flavonoids 
found m Blumea balsamifera DC leaves and butylated 
hydroxyanisole (BHA), on 1,1-diphenyl-2-picrylhydrazyl (DPPH) 
radical. BHA was used as reference compound. 
Free radical scavenging activity of flavonoids [BL-VI (blumeatin), 
BL-VIII (tamarixetin) and BL-XIII (5,7 ,3',5'-
tetrahydroxyflavanone)] found in Blumea balsamifera DC leaves 
measured using the DPPH assay. Results are mean± S.D (n;::; -3). a-
Tocopherol (TOC), butylated hydroxytoluene (BHT), butylated 
hydroxyanisoie (BHA) and L-Ascorbic acid (AA) were used as 
reference compounds. 
Free radical scavenging activity of rhamnetin (BL-IX), luteolin-7-
methyl ether (BL-X), luteolin (BL-XI) and quercetin (BL-XII) found 
in Blumea balsamifera DC leaves measured using the DPPH assay. 
Results are mean ± S.D (n = 3) . 
Free radical scavenging activity of dihydroquercetin-4',7-dimethyl 
ether (BL-V) and dihydroquercetin-4' -methyl ether (BL-XIV) found 
in Blumea balsamifera DC leaves measured using the DPPH assay. 
Results are mean± S.D (n = 3). 
The concentration of different solvent extracts of Blumea 
balsamifera DC leaves vs. the inhibition of xanthine oxadase. Results 
are mean± S.D (11 = 3). 
The concentration of different solvent extracts of Blumea 
balsamifera DC leaves vs. scavenging of superoxide radicals 
(Enzymatic). Results are mean± S.D (n = 3). 
The concentration of flavonoids (BL-IX, BL-X, BL-Xll, BL-Xill 
and BL-XIV) vs. inhibition of xanthine oxidase, the enzyme that 
produces uric acid and superoxide radicals. Results are mean ± S.D 
(n = 3). 
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4.22: The concentration of flavonoids (BL-VI, BL-VID and BL-XI) and 204 
reference compound (ascorbic acid) vs. inhibition of xanthine 
oxidase, the enzyme that produces uric acid and superoxide radicals. 
Results are mean± S.D (n = 3). 
4.23: The concentration of flavonoids (BL-IX, BL-X, BL-Xll, BL-XID 205 
and BL-XIV) vs. scavenging of enzymatically generated superoxide 
radicals. Results are mean± S.D (n = 3). 
4.24: The concentration of flavonoid (BL-VI, BL-VID and BL-XI) and 205 
reference compound (ascorbic acid) vs. scavenging of enzymatically 
generated superoxide radicals. Results are mean ± S.D (n = 3). 
4.25: The inhibitory effect of allopurinol and superoxide dismutase (SOD) 206 
on the production of uric acid and superoxide radicals from xanthine 
oxidase (XO). Results are mean± S.D (n = 3). 
4.26: The non-enzymatically generated superoxide radicals scavenging 210 
activities of different solvent extracts of the leaves of Blumea 
balsamifera DC. Values are mean of triplicate analysis. 
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4.33: 
4.34: 
The non-enzymatically generated superoxide radicals scavenging 
activities of the flavonoids (100 ,uM) of the leaves of Blumea 
balsamzfera DC. Values are mean of triplicate analysis. 
Calcium oxalate dihydrate crystal (COD) in control and PEB (pet 
ether extracts of Blumea balsamifera DC) at 24 hours (x 10). 
Calcium oxalate dihydrate cryst!!l (COD) in control and CEB 
(chloroform extracts of Blumea balsamifera DC) at 24 hours (x 10). 
Calcium oxalate dihydrate crystal (COD) in control and MEB 
(methanol extracts of Blumea balsamifera DC) at 24 hours (x 10). 
Calcium oxalate dihydrate crystal (COD) in control and CECS 
(chloroform extracts of com silk) at 24 hours (x 10). 
Calcium oxalate dihydrate crystal (COD) in control and MECS 
(methanol extracts of com silk) at 24 hours (x 10) 
Inhibition index of calcium oxalate crystals by different solvent 
extracts of Blumea balsamifera DC and com silk (without urine) at 
24 hours. Results are mean± S.D (n = 3). MB (methylene blue) was 
used as reference compound. 
Calcium oxalate dihydrate crystals (COD) m control and MB 
(methylene blue) at 24 hours (x 10). 
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4.35: Calcium oxalate dihydrate crystals (COD) in control and AP 238 
(allopurinol) at 24 hours (x 10). 
4.36: Calcium oxalate dihydrate crystals (COD) in control and BL-VI 239 
(blumeatin) at 24 hours (x 10). 
4.37: Calcium oxalate dihydrate crystals (COD) i;~ control and BL-XI 240 
(luteolin) at 24 hours (x 10). 
4.38: Calcium oxalate dihydrate crystals (COD) in control and BL-XII 241 
(quercetin) at 24 hours (x 10). 
4.:N: Calcium oxalate dihydrate crystals (COD) in control and BL-XIIT 242 
(5,7,3',5'-tetrahydroxyflavanone) at 24 hours (x 10). 
4.40: Growth rate inhibition of calcium oxalate crystals relative to control 243 
(%)by flavonoids [BL-VI (blumeatin), BL-Vill (tamarixetin), BL-IX 
(rhamnetin), BL-XI (luteolin), BL-XII (quercetin), BL-XIIT 
(5,7,3',5'-tetrahydroxyflavanone) and BL-XIV (dihydroquercetin-4'-
methyl ether)] and chemical inhibitors [MB (methylene blue) and AP 
(allopurinol) at different time intervals. Results are mean ± S.D (n = 
3). [Appendix B(1)]. 
4.41: Inhibition index of calcium oxalate crystals by flavonoids [BL-VI 244 
(blumeatin), BL-Vill (tamarixetin), BL-IX (rhamnetin), BL-XI 
(luteolin), BL-XII (quercetin), BL-XIIT (5,7,3',5'-
tetrahydroxyflavanone) and BL-XIV (dihydroquercetin-4'-methyl 
ether)] and chemical inhibitors [MB (methylene blue) and AP 
(allopurinol)] at 24 hours. Methylene blue and allopurinol were used 
as reference compounds. Results are mean± S.D (n = 3). 
4.42: Inhibition index of calcium oxalate crystals by different solvent 248 
extracts of Blumea balsamifera DC and com silk in normal urine 
(NU) at 24 hours. Results are mean ± S.D. (n = 3). MB (methylene 
blue) was used as reference compound. 
[A] Inhibition index in presence of normal urine (NU) 
[B] Inhibition index in presence of stone former urine (SF) 
4.43: Growth rate inhibition of calcium oxalate crystals relative to control 252 
(%)by flavonoids [BL-VI (blumeatin), BL-Vill (tamarixetin), BL-IX 
(rhamnetin), BL-XI (lutcolin), BL-Xll (quercetin), BL-Xlll 
(5,7,3',5'-tetrahydroxyfiavanone) and BL-XIV (dihydroquercetin-4'-
methyl eLher)] and chemical inhibitors [MB (methylene blue) and AP 
(allopurinol)] in normal urine (NU) at different time intervals. 
Resuits are mean ± S.D (n = 3). [Appendix B(2)]. 
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4.44: Growth rate inhibition of calcium oxalate crystals relative to control 253 
(%) by flavonoids [BL-VI (blumeatin), BL-Vill (tamarixetin), BL-IX 
(rhamnetin), BL-XI (luteolin), BL-XII (quercetin), BL-Xlll 
(5,7 ,3' ,5'-tetrahydroxyflavanone) and BL-XIV (dihydroquercetin-4'-
methyl ether)] and chemical inhibitors [MB (methylene blue) and AP 
(allopurinol)] in stone former urine (SF) at different time intervals. 
Results are mean± S.D (n = 3). [Appe!ldix B(3)]. 
4.45: Inhibition index of calcium oxalate crystals by flavonoids [BL-VI 254 
(blumeatin), BL-Vill (tamarixetin), BL-IX (rhamnetin), BL-XI 
(luteolin), BL-Xll (quercetin), BL-Xlll (5,7,3',5'-
tetrahydroxyflavanone) and BL-XIV (dihydroquercetin-4'-methyl 
ether)] and chemical inhibitors [MB (methylene blue) and AP 
(allopurinol)] at 24 hours. Results are mean± S.D. (n = 3). 
[A] Inhibition index in presence of normal urine (NU) 
[B) Inhibition index in presence of stone former urine (SF) 
4.46: Calcium-flavor.oid complex 259 
4.4 7: Changes of UV -spectrum of flavonoids of Blumea balsamifera DC in 261 
presence of CaCh. 
4.48: !socratic reversed phase HPLC analysis of flavonoid standards 271 
isolated from the ieaves of of Blumea balsamifera DC. Peak 
• 
4.49: 
4.50: 
4.51: 
numbers: 1. Dihydroq'lercetin-4'-methyl ether (BL-XIV); 2. 
3,5,3',5'-tetrahydroflavanone (BL-Xill); 3. Quercetin (BL-XII); 4. 
Dihroquercetin-7,4'-dimethyl ether (BL-V); 5. Blumeatin (BL-VI) . 
Calibration curve of five flavonoids [BL-V (dihydroquercetin-7,4'-
dimethyl ether), BL-VI (blumeatin), BL-XII (quercetin), BL-XIII 
(5,7,3',5' -tetrahydroxyflavanone), and BL-XIV (dihydroquercetin-4'-
methyl ether)] of Blumea balsamifera DC in methanol. 
!socratic RP-HPLC analysis of Blumea balsamifera DC leaves 
extract coilected from different regions of Malaysia. Peak numbers: 
1. Dihydroquercetin-4'-methyl ether (BL-XIV); 2. 3,5,3',5'-
tetrahydroflavanone (BL-XIII); 3. Quercetin (BL-XII); 4. 
Dihroquercetin-7 ,4' -dimethyl ether (BL-V); 5. Blumeatin (BL-VI). 
Calibration curve of five flavonoids [BL-V (dihydroquercetin-7,4'-
dimethyl ether), BL-VI (blumeatin), BL-XII (quercetin), BL-Xill 
(5,7 ,3',5' -tetrahydroxyflavanone), and BL-XIV (dihydroquercetin-4'-
methyl ether)] of Blumea balsamifera DC in rat plasma. 
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4.52: Chromatogram of blank plasma (A), spiked standard (B) (1 J.lg/mL) 283 
and rat plasma at 1 hr after oral administration of Blumea 
balsamifera leaves extract (C). Peak identification: I = 
dihydroquercetin-4'-methyl ether (BL-XIV); II = 5,7,3',5'-
tetrahydroxyflavanone (BL-Xill); ill = naringenin (IS); IV = 
quercetin (BL-XII); V = dihydroquercetin-7,4'-dimethyl ether (BL-
V); VI= blumeatin (BL-VI). 
4.53: Plasma concentration vs. time profiles for BL-V, BL-VI, BL-XII, 284 
BL-Xill and BL-XIV in rats following oral administration of lglkg 
of extracts of the leaves of Blumea balsamifera DC . 
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KAJIAN FITOKIMJ I\ DAUN BLUMEA BALSAMIFERA DC DAN BENANG 
SARI JAGill.;G ZEA MAYS L DAN PENILAIAN IN VITRO KEGUNAANNYA 
DALAM UROLITIASIS 
ABSTRAK 
Daun Blumea balsamifera dan benang sari jagung Zea mays digunakan secara 
tradisional bagi keadaan yang berkaitan dengan urolitiasis. Drug-drug mentah Blumea 
balsamifera dinilai menggunakan parameter kawalan mutu yang termasuk analisis-
analisis mikroskopi, makroskopi, gravimetri, kromatografi lapisan nipis dan elusi 
kecerunan kromatografi cecair prestasi tinggi fasa terbalik (RP-HPLC). 
Penyelidikan fitokimia ke atas ekstrak-ekstrak pet-eter, kloroform dan metanol 
daun Blumea balsamifera berjaya memencilkan dua hidrokarbon, dua fitosterol dan 
sebeias flavonoid. Campuran empat asid lemak, dua fitosterol dan tiga flavonoid telah 
dipencilkan daripada benang sari jagung Zea mays. Identiti struktur sebatian-sebatian ini 
• 
telah ditentukan dengan menggunakan pelbagai kaedah analitikal sep~rti UV, IR, lD 
NMR, MS, X-Ray dan analisis unsur. 
Kapasiti antioksidan pelbagai ekstrak pelarut dan flavonoid Blumea balsamifera 
telah dinilaikan dengan kaedah-kaedah yang telah digunakan secara meluas. Ekstrak 
metanol menunjukkan aktiviti antioksidan lebih tinggi apabila dibandingkan dengan 
ekstrak-ekstrak kloroform dan pet-eter. Hubungan struktur-aktiviti yang berbeza juga 
telah menunjukkan kecekapan antioksidan flavonoid-flavonoid tersebut. Kehadiran 
pengganti hidroksil pada nukleus flavonoid meninggikan aktiviti antioksidan, manakala 
penggantian oleh kumpulan metoksi menurunkan aktiviti antioksidan sebatian-sebatian 
tersebut. Hal ini menunjukkan bahawa struktur kimia ialah penentu aktiviti antioksidan 
sebatian-sebatian tersebut. Keputusan daripada kajian ini memberikan bukti bahawa 
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• 
ekstrak claun Blumea balsamifera dan flavonoid-flavonoidnya menunjukkan sifat-sifat 
antioksidan yang menarik yang dinyatakan samada dengan mempunyai kapasiti untuk 
mengaut radikal bebas atau radikal superoksida, atau mempunyai kapasiti untuk 
merencat aktiviti xantine oksidase, suatu enzim yang terlibat dalam penghasilan asid 
urik. 
Kesan ekstrak-ekstrak daun Blumea balsamifera, benang sari jagung Zea mays 
dan flavonoid-flavonoid terpencil Blumea balsamifera terhadap kadar pertumbuhan in-
vitro kristal kalsium oksalat telah ditentukan dengan menggunakan kaedah Schneider 
slaid gel terubahsuai yang digabungkan dengan sistem penganalisis imej (Image 
Analyzer System). Ekstrak metanol dari kedua-dua sumber tumbuhan memberikan 
aktiviti perencatan lebih tinggi berbanding dengan ekstrak-ekstrak kloroform dan pet-
eter dalam pertumbuhan in vitro kristal kalsium oksalat dalam urin manusia dan tanpa 
urin. Tambahan pula, dalam ujian saringan antimikrobial, ekstrak-ekstrak Blumea 
balsamifera, benang sari jagung dan empat flavonoid terpencil Blumea balsamifera 
menunjukkan aktiviti spekturm luas terhadap bakteria patogen. 
Suatu kaedah isokratik RP-HPLC dengan pengesan UV yang mudah, peka dan 
mempunyai kebolehulangan telah dibangunkan bagi penentuan kuantitatif lima 
flavonoid major dalam daun Blumea balsamifera. Kaedah yang telah dibangunkan 
diaplikasikan untuk penentuan serentak flavonoid-flavonoid ter$ebut dalam plasma 
tikus. Prosedur pengekstrakan bagi flavonoid dari plasma tikus adalah mudah dan 
purata pemulihan flavonoid tersebut dari plasma adalah dari 90 hingga 93%. Variasi 
dalam sehari dan variasi hari ke hari adaiah daiarn julat nilai yang boleh diterima 
( < 10% ). Parameter farmakokinetik bagi flavonoid ditentukan selepas dos 1 glkg ekstrak 
diberikan secara oral kepada tikus. Keputusan menunjukan penyerapan dan pengesanan 
yang baik. 
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ABSTRACT 
The leaves of Blumea balsamifera DC and com silk of Zea mays L are 
traditionally used in conditions related to urolithiasis. The crude drugs of Blumea 
balsamifera were evaluated using quality control parameters, which includes 
microscopic, macroscopic, gravimetric, thin layer chromatographic and gradient 
reversed-phase high-performance liquid chromatographic (RP-HPLC) analysis. 
Phytochemical investigation on pet-ether, chloroform and methanol extracts of 
the leaves of Blumea balsamifera resulted in the isolation of two hydrocarbons, two 
phytosterols and eleven flavonoids. Mixtures of four fatty acids, two phytosterols and 
three flavonoids were isolated from the com silk of Zea mays. The structural identity of 
these compounds was determined by means of different analytical methods such as UV, 
IR, lD NMR, 2D NMR, MS, X-Ray and elemental analysis. 
The antioxidant capacity of different solvent extracts and isolated flavonoids of 
. 
Blumea balsamifera was evaluated using widely used methods. Methanol extracts 
exerted higher antioxidant activity as compared to chloroform and pet-ether extracts. 
The four classes of isolated flavonoids of Blumea balsam(fera exhibited various ranges 
of antioxidant activities. Distinct structure-activity relationships were also revealed for 
the antioxidant abilities of the flavonoids. The presence of hydroxyl substituents on the 
flavonoid nucleus enhanced activity, whereas the substitution by methoxyl groups 
diminished antioxidant activity. It appeared that the chemical structure of these 
compounds was a dete1minant to their antioxidant activity. The results of this study 
provided evidence that Blumea balsamifera leaves extract and their flavonoids exhibited 
interesting antioxidant properties, expressed either by its capacity to scavenge fret 
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radicals or superoxide radicals or its capacity to inhibit xanthine oxidase activity, an 
enzyme involved in uric acid production. 
The effects of extracts of the leaves of Blumea balsamifera and corn silk of Zea 
mays, and isolated flavonoids of Blumea balsamifera on the in vitro growth rate of 
calcium oxalate crystals were determined using modified Schneider's gel slide method 
in association with the Image Analyzer System. Methanol extracts of both plant sources 
exe:ted higher inhibitory activity as compared to chloroform and pet-ether extracts on in 
vitro growth of calcium oxalate crystals in absence and presence of human urine. 
Flavonoids with free hydroxyl group at C-3, C-3' and C-4' position showed higher 
inhibitory activity than their methoxylated compounds. In addition, in antimicrobial 
screenmg test, extracts of Blumea balsamifera and corn silk, and isolated four 
flavonoids of Blwnea balsamifera exerted broad-spectrum activity towards pathogenic 
bacteria. 
A simple, sensitive and reproducible isocratic RP-HPLC method using UV 
detection was developed for the quantitative determination of five major flavonoids in 
leaves of Blumea balsamifera. The developed method was applied for the simultaneous 
determination of these flavonoids in rat plasma. The extraction procedure for the 
flavonoids from the rat plasma was simple and the mean recoveries of these flavonoids 
from plasma range from 90 to 93%. The within-day and the day-to-day variations were 
within the acceptable value ( <1 0% ). The pharmacokinetic parameters of the flavonoids 
were determined foilowing oral dosing of lg/kg extracts in rats. The results showed 
good absorption and detectability. 
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Chapter 1: INTRODUCTION 
1.1 PREAMBLE 
Kidney stone disease is a multi-factorial disorder resulting from metabolic 
abnormalities influencing the composition of body fluids and urine. It affects about 1-
3% of the population and the recurrence rate is quite high, about 50% at 10 years and 
75% at 15 if untreated (Balaji & Menon, 1997). Several factors such as heredity, age 
and sex, geographical factors, climate, rac_e, and diet have been suggested for the 
etiology of stone disease (Smith, 1989). The majority of upper urinary stones are 
composed of calcium oxalate and calcium phosphate and usually occur in men, while 
most stones of magnesium and ammonium phosphate occur in the bladder, mostly in 
women (Smith, 1978). 
The principal causative factor for the formation of calcium salt stones is 
.attributed to the supersaturation of precipitating salts (Robertson, 1976; Menon & Koul, 
1992). Even though urine is supersaturated with calcium and oxalate ions in normal 
subjects, they do not form stones because of the presence of smaller sized crystals and 
qualitatively improved inhibitors and/or larger quantities of inhibitors (Robertson & 
Peacock, 1972; Backman et al., 1984) that are normally deficient in stone formers. 
Calcium oxalate crystal itself was found to injure the membrane (Hackett et al., 
1994) that facilitated the fixation of calcium oxalate crystals and subsequent kidney 
stone (Khan et al., 1990; Khan & Hackett, 1991). Membrane injury was also mediated 
by lipid peroxidation reaction through the generation of oxygen free radicals and 
increased production of superoxide anion and hydroxyl radicals (Bijikurien & Selvam, 
1989), and increased both superoxide and H202 generating enzymes such as xanthine 
oxidase (Ravichandran & Selvam, 1990; Selvam & Ravichandran, 1991; Selvam & 
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Bijikurien 1992a; Adhirai & Selvam, 1998). Free radicals positively correlated with 
cellular oxalate, oxalate binding and calcium level and correlated negatively with 
antioxidant system (Ravichandran & Selvam, 1990; Selvam & Ravichandran, 1991). It 
appears that compounds having free radical scavenging properties could be promising 
remedy in calcium oxalate urolithiasis. 
A number of medicinal plants have been used traditionally in patients with 
kidney stone diseases including leaves of Blumea balsamifera DC and com silk of Zea 
mays L. The use of com silk in urological disorder is well. established and being used 
since the old days (Grieve, 1971). Though the leaves of Blumea balsamifera are used as 
a folk medicine in kidney stone diseases in South-East Asia (Burkill, 1966), but there 
are no studies to supports its medical uses. In view of these, the present work was aimed 
to isolate the bioactive compounds from the leaves of Blumea balsamifera and com silk 
of Zea mays. 
Among the numerous substances identified in medicinal plants, flavonoids 
• 
represent one of the most interesting groups biologically active compound. Due to their 
presence both in edible plants and foods and beverages derived from plants, flavonoids 
are important constituents of the non-energetic part of the human diet (Manach et al., 
1996). It has been found that they possess antioxidant and free radical scavenging 
activity in foods (Shahidi & Wanasundara, 1992) and several studies have indicated that 
their consumption is associated with a reduced risk of cancer (Wattenburg, 1985, 1990; 
Wei t:r ai., 1990; Hertog et al., 1994; Verma et al., 1998). Flavonoid preparations have 
iong been used in medical practice to treat disorders of peripheral circulation, to lower 
blood pressure and to improve aquaresis (Jaeger et al., 1988). Many of these alleged 
effects of pharmacological doses of flavonoids are linked to their known functions as 
strong antioxidants, free radical scavengers, metal chelators (Kaur & Perkins, 1991; 
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Shahidi & Wanasundara, 1992; van Acker et al., 1996a) and their interaction with 
enzymes and biomembranes (Esterbauer et al., 1992; Formica & Regelson, 1995; Saija 
et al., 1995; Ji et al., 1996). The study on these chemical and biochemical properties of 
flavonoids can be em?loyed to evaluate the medicinal value of the flavonoids and 
flavonoids rich extracts of the leaves of Blumea balsamifera. 
The antioxidant activities of plant extracts cannot be evaluated by only a single 
method due to the complex nature of phytochemicals present in plants. Therefore, 
commonly accepted assays, including lipid peroxidation inhibitory activity, free radical 
scavenging activity, the xanthine oxidase inhibitory and superoxide scavenging 
activities using the ·enzymatic and non-enzymatic methods, can be employed to evaluate 
the total antioxidant effects of Blumea balsamifera leaves and its flavonoids. The 
chemical structure of flavonoids is a large determinant for the antioxidant activity. 
Establishment of structure activity relationship for flavonoids will allow for their 
selection as antioxidants based on structure alone, without having to screen every 
• 
possible compound for activity. 
The polyphenolic structure of flavonoids confers them with the ability to 
scavenge free radicals and chelate metal ions such as iron, copper and calcium 
(Afanas'ev et al., 1989; Raihan, 1992; Morel et al., 1994; van Acker et al., 1996a; 
Ismail et al., 1999). The antioxidant and metal chelating properties of these compounds 
can be employed to determine the effect of flavonoids on the in-vitro growth rate of 
calcium oxalate crystals, as it is a most important constituent of kidney stone. In 
addition, the test can be carried out in the presence of human urine. The positive 
inhibitory effect of flavonoids and flavonoids rich extracts as well as their potential 
antioxidant properties will allow the selection for flavonoids and extracts as 
antiurolithic agents. 
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The urinary tract infections by bacteria affect the structure and function of the 
kidneys and can chemically affect the urine itself leading to stone formation, known as 
"struvite" or infection stones (Savitz & Leslie, 2003). Therefore, the antibacterial 
studies on the extracts and flavonoids of the leaves of Blumea balsamifera and corn silk 
of Zea mays, can be carried out to strengthen their medicinal use in urolithiasis. 
Upon evaluation of medicinal potential of flavonoid rich extracts, a sensitive and 
accurate reversed-phase high-performance liquid-chromatographic (RP-HPLC) method 
need to be developed to determine these flavonoids present in extracts of the leaves of 
Blumea balsamifera for standardization of the crude drug. The developed method can 
be applied for quantification of flavonoids in rat plasma following oral administration of 
the crude drugs in rats in order to support pre-clinical phannacokinetic studies. 
1.2 OBJECTIVES OF THIS RESEARCH 
• The present work was undertaken with the following objectives: 
1. To study on the chemical constituents of the leaves of Blumea balsamifera and 
corn silk of Zea mays and to establish a fairly comprehensive data on the 
compounds isolated from these plants. 
2. To evaluate the medicinal value of the extracts and flavonoids of the leaves of 
Blumea balsamifera and corn silk of Zea may by means of several studies 
related to antioxidant, antiurolithic and antibacterial activities, and to establish 
the structure-activity relationship for the studied flavonoids. 
3. To develop an accurate and sensitive RP-HPLC method for the quantification of 
flavonoids of crude drugs and to evaluate the pharmacokinetic profiles for the 
extracts ~f the leaves of Blumea balsamifera to promote the development of 
standardized phytomedicine. 
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Chapter 2.0: LITERATURE REVIEW 
2.1 KIDNEY STONES DISEASE 
The medical terminology for kidney stone is nephrolithiasis or urolithiasis. A 
kidney stone is a solid lump made up of crystals that separate from urine and build up 
on the inner surfaces of the kidney. Kidney stone diseases are one of the most common 
disorders of the urinary tract. It is estimated that one to five per cent of the population 
will develop stones at some point in life. 
There are geographical, temporal and ethnic correlations of stone formation that 
reinforce the notion that stones are symptoms arising from multipie causes (King, 
1971 ), like from malnutrition and vitamin deficiency (Bergmann & Nagel, 1982), more 
industrialized country (Li et al., 1985) and high standard of living (Borghi et al., 1990; 
Savitz & Leslie, 2003). In less well-developed countries in Asia, Anderson (l973) 
reported dietary factors are the principle factor for kidney stone diseases such as a 
• 
deficiency in protein, less fat in food, and dependence on vegetable as the main source 
of protein may be the principal dietary factors. 
A high incidence of renal stone, were also observed in people who lived in the 
tropical countries for a sufficient long period. Incidence of stones in Peninsular 
, Malaysia appears to show the same trend as in other industrialized countries. This rise is 
due to the rapid physical development and change in the food habits of the people. In 
1980, the incidence of urinary calculi in Malaysia was estimated at J4.9 per 1,00,000 
population (Srecnevasan, 1990). Recurrence of stone disease occurs in 60% of adults 
within 9 years of the initial episode (Sreenevasan, 1990). It is a challenge to reduce the 
high recurrence rate of this painful condition. Therefore, identification and treatment of 
predisposing causes are important, to prevent recurrence of kidney stone. 
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2.1.1 TYPES OF KIDNEY STONES 
2.1.1.1 Calcium oxalate stone 
The most common kidney stone is the calcium oxalate stone. When the body's 
calcium, an abundant mineral throughout the system and a compound called oxalate 
combine in the kidneys, they form an insoluble salt that can easily tum into a stone. 
Some 85% of all kidney stones are calcium oxalate stones (Coe, 1978; Savitz & Leslie, 
2003). 
2.1.1.2 Calcium phosphate stone 
Calcium phosphate stones are less common. Both calcium and phosphate are 
very abundant in the body, and calcium phosphate crystals stiffen the bones and make 
them rigid. The body eliminates large amounts of phosphate through the urine every 
day, but if one suffers from a condition that increases calcium output in the urine, which 
makes the urine more alkaline, the calcium combines with the abundant phosphate in 
the urine and produces stones. Most calcium oxalate stones have a certain amount of 
calcium phosphate material in them (Badenoch, 1974; Savitz & Leslie, 2003). 
2.1.1.3 Uric acid stones 
Uric acid stones are much less common than calcium oxalate stones. Sometimes 
they are made up of pure uric acid, and sometimes they form as a mixture of uric acid 
with calcium oxalate. The body makes uric acid when it breaks down RNA and DNA as 
a normal body function. Uric acid can crystallize into stones when the urine is 
persistently acid. About 10% of stones are made of uric acid (Badenoch, 1974; Savitz & 
Leslie, 2003). 
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2.1.1.4 Struvite 
Struvite stones are made up of magnesium, ammonium and phosphate. They 
always result from infection. During a urinary infection, certain bacteria can break down 
urea, which is a component of urine, into ammonia. This makes the urine surrounding 
the bacteria extremely alkaline, so that the magnesium and phosphorus, which normally 
present in the urine form crystals with the ammonia. About 9% to 17% of stones are 
struvite (Savitz & Leslie, 2003). 
2.1.1.5 Cystine stone 
This type of stone is much less common. It is made up of the amino acid, 
cystine, and occurs only with patients suffering from a genetic disease called cystinuria. 
Children who get kidney stones may get cystine stones, since the condition is 
hereditary. About 1% of stones are made of cystine (Savitz & Leslie, 2003) . 
2.1.2 CAUSES OF CALCIUM OXALATE STONE 
Two third of all kidney stones are made of calcium oxalate or mixed with 
calcium phosphate (Wardle, 1979; Sidabutar, 1981; Savitz & Leslie, 2003). The 
majority of patients, 85 percent, formed calcium oxalate stones were not due to specific 
diseases but to idiopathic hypercalciuria, hyperuricosuria, mild hyperoxaluria, or 
hypocitraturia (Solomon, 1978; Savitz & Leslie, 2003). The most common cause of 
calcium stone production is excess calcium in the urine termed as hypercalciuria. 
Excess calcium is normally removed from the blood by the kidneys and excreted in the 
urine. In hypercalciuria, excess calcium builds up in the kidneys and urine, where it 
combines with other waste products to form stones (Dent & Watson, 1965; Nakada et 
al., 1988). Low levels of citrate, high levels of oxalate and uric acid, and inadequate 
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urinary volume may also cause calcium stone formation (Robertson & Peacock, 1980; 
Kok et al., 1986; Embon et al., 1990). 
Increased intestinal absorption of calcium termed as absorptive hypercalciuria, 
excessive hormone levels as in hyperparathyroidism, and renal calcium leak results 
from kidney defect that causes excessive calcium to enter the urine, can cause 
hypercalciuria and therefore may cause calcium stones (Badenoch, 1974; Solomon, 
1978; Schwille, 1979; Savitz & Leslie, 2003). 
Diet plays an important role in the development of calcium oxalate stones, 
especially in patients who are predisposed to the condition (Robertson, 1987; Trinchieri 
eta!., 1991; Heller et al., 2003). A diet high in sodium, fats, meat, and sugar, and low in 
fiber; vegetable protein, and unrefined carbohydrates increases the risk for renal stone 
disease (Breslau et al., 1982; Brockis et al., 1982). Recurrent kidney stones may form in 
patients who are sensitive to the chemical byproducts of animal protein and who 
consume large amounts of meat (Robertson et al., 1979; Kok et al., 1990a). 
Hyperoxaiuria, a condition of high levels of oxalate ill urine also responsible for 
calcium stones formation. High doses of vitamin C (i.e., more than 500 mg per day) can 
result in high levels of oxalate in the urine and increase the risk for calcium oxalate 
stones. Food containing high levels of oxalate, such as berries, vegetables (e.g., green 
beans, beets, spinach, squash, tomatoes), nuts, chocolate, and tea are also responsible 
for calcium oxalate stone (Brinkley et al., 1981; Trinchieri et al., 1991). 
Hyperuricosuria, causes increased urinary uric acid excretion is also associated 
with calcium oxalate stone. The mechanism may be the deposition of calcium oxalate 
crystals upon uric acid crystals. Hyperuricosuria may either be isolated or associated 
with hypercalciuria. Treatment is with allopurinol, an agent that reduces uric acid 
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excretion, and with restriction of excess purine and animal protein intake (Solomon, 
1978; Coe, 1983). 
Hypercalciuria condition is generally treated by both counseling against certain 
dietary excesses, and by drug administration. Patients are advised against a calcium 
intake of more than 1 g per day, and a high sodium intake. The most commonly used 
drug treatment consists of thiazide diuretics, which reduce renal calcium excretion 
(Wardle, 1979). 
Ebisuno et al. (1986) reported that rice bran effectively reduces urinary calcium 
excretion by reducing the intestinal absorption of calcium and may be effective in 
preventive urinary calcium stone. Proper hydration prevents the urine from becoming 
concentrated with crystals, which leads to stone formation; and it reduces the risk of 
urinary tract infections, which reduces the risk of formation of stones (Wardle, 1979; 
Embon et al., 1990). 
Human urine 1s normally supersaturated with respect to calcium oxalate 
• 
hydrates, octac<!lcium phosphate [Cf4H(P04)3, OCP], hydroxyapatite [Ca.>(P04)0H, 
HAP] and sometimes dicalcium phosphate dihydrate [Ca2HP04.2H20, DCPD]. The 
degree of supersaturation is usually higher in stone former patients mainly because they 
tend to have higher urinary calcium (Nancollas, 1983). Many non-stone formers have a 
higher than normal urinary calcium excretion, and their urine are saturated with respect 
to calcium oxalate and calcium phosphate, yet crystallization does not occur. Along 
with saturation of urine, other factors are also involved in stone formation (Dent & 
Sutor, 1971). 
Randall (1937) suggested that renai cell injury is an important factor that 
facilitates the retention and subsequently the formation of renal calculi. Experimentai 
evidence suggested that oxalate induced membrane injury was mediated uy lipid 
9 
peroxidation (LPO) reaction through the generation of oxygen free radicals (Scheid et 
al., 1996; Thamilselvan et al., 1997; Thamilselvan et al., 2000). In urolithic rat kidney 
or oxalate exposed cultured cells, both superoxide anion and hydroxyl radicals were 
generated in excess, causing cellular injury (Bijikurien & Selvam, 1989). In 
hyperoxaluric rat kidney, both superoxide and H20 2 generating enzymes such as 
xanthine oxidase were increased (Ravichandran & Selvam, 1990; Selvam & 
Ravichandran, 1991; Selvam & Bijikurien, 1991, 1992a; Adhirai & Selvam, 1998) and 
hydroxyl radicals and transitional metal ions, iron and copper were accumulated 
(Ravichandran & Selvam, 1990, 1991; Selvam & Ravichandran, 1991). The lipid 
peroxidation products were excessively released in tissues of urolithic rats and in 
plasma of rats as well as in stone patients (Scheid et al., 1996; Thamilseivan et al., 
2000). The accumulation of these products was concomitant with the decrease in the 
antioxidant enzymes such as superoxide dismutase (SOD) as weli as radical scavengers, 
vitamin E and ascorbic acid (Ravichandran & Selvam, 1990, 1991; Selvam & 
Bijikurien, 1991, 1992a). All these parameters were decreased in the urolithic condition, 
irrespective of the agents used for the induction of urolithiasis. 
Slater (1984) reported that antioxidant therapy to urolithic rats prevented cell 
damage by preventing free radical mediated diseases in urolithiasis. Citrate or 
magnesium citrate was advocated to stone patients, and the reduction of excretion of 
stone risk factors was attributed to its complex formation with calcium, thereby 
preventing calcium oxalate crystal formation (Lee et al., 1999). However, citrate 
treatment had no effect on free radical-mediated reactions in experimental urolithiatic 
rats, on either reducing lipid peroxidation (LPO) or improving antioxidant levels, even 
though it prevented stone formation (Selvam & Bijikurien, 1992b). 
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2.1.3 THEORIES OF STONE FORMATION 
The initial step in the formation of stone- is the development of a nidus. A stone 
can form only when urine is supersaturated with respect to its constituent crystals. 
Supersaturation means that the concentration of a stone forming salt, such as calcium 
oxalate, exceeds its solubility in urine. Urine of most non-stone formers is 
supersaturated with respect to calcium oxalate, so in principle all non-stone formers can 
form such stones (Robertson, 1977; Savitz & Leslie, 2003). Normal urine is not 
supersaturated with respect to uric acid, cystine or struvite. Conditions that raise 
calcium oxalate supersaturation raise the risk of calcium oxalate stones. Several 
mechanisms have been postulated for the formation of stones in the 'urinary tract, such 
as supersaturation of stone-forming ionic species, extacellular matrix nucleation, 
absence of inhibitors and cell injury leading to attachment of crystals followed by 
retentions of the crystals by the renal cells. 
Increased concentration of crystal forming substances occur if the volume of 
• 
urine is significantly reduced or there are abnormally higher amounts crystal forming 
substances, such as calcium, oxaiate, uric acid, cystine or xanthine, being excreted in the 
urine. Fifty percent of all calcium stone former have increased urinary excretion of 
calci urn or oxalate salts (Dent & Sutor, 1971; Robertson & Peacock, 1972; Drach et al., 
1980). 
The inhibitor-absence theory indicates that normal urine contains inhibitors of 
crystal formation. Inhibitors of nucleation may include certain peptides, magnesium, 
citrate, pyrophosphate, and other substances that prevent or inhibit stone-building 
substances from forming crystals. Low levels of these inhibitors can contribute to the 
formation of kidney stones. Of these, citrate is thought to be the most important. 
Changes of the pH of the urine that causes acid or alkaline imbalances can also affect 
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stone precipitation (Soloman, 1978; Nancollas, 1983; Kok et al., 1990a; Fuselier et al., 
1998). 
The extacellular matrix nucleation theory implies that a urinary substance such 
as mucoprotein forms the initial matrix around which the crystalloid is deposited. The 
factors predisposes to matrix formation is unknown but some data suggest that 
nucleation of calcium phosphate monohydrate (brushite) is the initial step in the 
formation of stones containing calcium phosphate alone or mixed with calcium oxalate 
(Sallis, 1987; Baumann, 1990). 
Cell injury is the primary event for crystal binding. In order for the renal cell to 
retain calcium oxalate crystals, the crystals should bind to the cell primarily. In support 
of this, Randall ( 1937) was the first to show initiation of renal calculi to occur as 
subepithelial calcified plaques in the renal papilla, both in the inlerstitium and within 
the nephronic duct. Carr (1953) had observed renal calculi formation following the 
obstructions of the lymphatic system in the form of small radiographic opacities (Carr 
. 
bodies) that were found in all the kidneys from stone-forming patients. He observed that 
the presence of renal cavities with low urodynamic efficacy retain urine for long periods 
of time, favoring calculus formation. In these studies, it is evident that both molecular 
adhesion and stagnation of crystals in an anatomically constrained region play a vital 
role for the pathogenic mechanism in the growth of renal stones. 
Free calcium oxalate crystals formed within the renal tubule cannot grow rapidly 
enough to block a collecting duct at the rate of normal urinary flow and become a 
kidney stone, because the time needed for a crystal to grow to a diameter of 200 J.tm and 
block the nephron is calculated to be from 90 min to 1500 years (Finlayson, 1974). So 
Finlayson & Reid (1978) concluded that, in order to form a stone, the crystals should be 
attached to the epithelium, and they suggested the fixed particle hypothesis. In support 
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of this, Vermuelen et al. (1967) demonstrated crystal retention in the rat renal papilla in 
experimentally induced crystalluric rat. The renal papilla was found to be the primary 
nucleation site because of the existence of oxalate and calcium gradient (Hautmann et 
al., 1981). The evidence for crystal attachment to the epithelial basal lamina in 
crytalluric rat kidney was presented by the studies of Khan et al. (1982). Mandel & 
Riese (1991) observed more crystals attachment to cells that have lost partial or 
complete intercellular junctional integrity. They suggested that membrane injury 
exposes the basolateral or basement membrane crystal-binding molecules, facilitating 
crystal attachment. Further studies using chemically injured urothelium (Gill et al., 
1979; Khan et al., 1982), gentamicin-pretreated rat kidney (Sigmon et al., 1991), or 
damaged epithelium with reduced glycosaminoglycan layer (Grases et al., 1993) were 
in support of membrane injury as the cause of the enhanced crystal retention. These 
findings have suggested that membrane injury plays a significant role as a predisposing 
factor for crystal binding and retention reaction . 
• 
Much attention was focused on oxalate-induced cell injury for the facilitation of 
crystal adherence (De Water et al., 1999; Scheid et al .. 2000). Hackett et al. (1994) 
reported that calcium oxalate crystals injured the membrane by interacting with the cell 
membrane and released the cellular contents. Similarly, in hyperoxaluria, renal tubular 
membrane injury was observed with excretion of enzymes of epithelial membrane 
origin. Further crystal deposition led to the detachment of the basement membrane, and 
membranous cellular degradation products were found to promote crystal formation and 
aggregatio11 (Khan et a!., 1990) and facilitate its retention. Bijikurien & Selvam (1989) 
supported that oxalate damaged the membrane by promoting lipid peroxidation (LPO) 
and suggested that increased LPO formation by oxalate was probabiy associated with 
the generation of oxygen free radicals such as superoxide radicals (02 •. ), hydroxyl 
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radicals (OH), lipid peroxidation (LPO) products and hydrogen peroxide (H20 2). Free 
radicals induced the cell injury and subsequently damaged cell layers favored the 
adherence of calcium oxalate crystals and intra-tubular stone formation (Selvam & 
Bijikurien, 1991; Muthukumar & Selvam, 1997; Selvam & Adhirai, 1997; Thamilselvan 
& Selvam, 1997; Grases et al., 1998; De Water et al., 1999; Scheid et al., 2000; Selvam 
• 
& Kalaiselvi, 2001) as shown in Figure 2.1. 
OXIDATIVE STRESS 
(HYPER OXALURIA) 
Normal epithelium with healthy layer 
I 
~ 
LPO induced oxalate/calcium oxalate 
binding to subcellular organelle 
Free radical (02·-. ·oH, LPO, H202) 
induced injury 
l 
Damaged layer favors crystal formation 
1 
LPO induced precipitation of crystals; 
Adherence of crystals and intra-tubular 
stone formation 
ANTIOXIDANT THERAPY 
Normal epithelium with healthy layer 
1 
No LPO induced effects 
No membrane injury 
1 
Inhibition of crystal adherence to 
membrane 
1 
No kidney stone formation 
Figure 2.1: Renal cell injury facilitates the adherence of calcium oxalate crystals and 
the preventive role of antioxidant therapy. 
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Grases et al. ( 1998) described the effect of free radicals on the development of 
calcium oxalate crystals on urothelium. They demonstrated that free radical-damaged 
cells produce a favorable environment for crystal development. At low free radical 
concentrations, crystals develop on calcium-enriched zones, whereas at higher 
concentrations, crystals develop on areas with a destroyed monolayer of superficial 
cells. Antioxidants, such as ascorbic acid and mannitol, exerted the most remarkable 
dfects in avoiding calcium oxalate crystal development, whereas crystal inhibitors, such 
as citric acid, did not produce any remarkable reduction in calcium oxalate 
crystallization. Phytic acid notably decreased calcium oxalate crystal development. The 
ability of phytic acid. to diminish calcium oxalate crystallization was attributed to the 
combination of its inhibit~I)· capacity o~ calcium oxalate crystallization and its 
preventive antioxidant action (Grases et al., 1998). 
Neprolithiasis, which was readily produced in control animals, was prevented in 
the experimental animal by pretreatment with fish oil and urine calcium was 
• 
significantly reduced. The urinary calcium and oxalate excretion in the recurrent 
hypercalciuric stone formers was significantly reduced with fish oil treatment. All these 
observations implicated the radical-mediated membrane changes, predisposing a 
favorable environment for subsequent crystal disposition and retention. Antioxidants 
can protect the membrane from injury and prevent adherence or retention of the crystals 
(Bigelow et al., 1997). 
2.1.4 NATURAL INHIBITORS IN URINE 
Human urine normally contains substances that can prevent the formation of 
calcium ox~late crystals and hence prevent the formation of stone (Nakagawa et al., 
1983). On the basis of molecular weight, inhibitors of calcium oxalate stone formation 
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have been classified into two groups. The low molecular weight material (10,000 
Daltons) probably accounts for approximately 80% of the total inhibition activity in 
urine (Sallis, 1987). It includes organic substances such as urea [1], citrate (2] or 
inorganic ionic substances such as magnesium, pyrophosphate [3] (Figure 2.2). It is 
believed that these substances act as inhibitors of stone formation by forming a soluble 
complex with the crystalline ions and/or by adsorption onto the crystal surfaces with 
subsequent blockage of further growth of crystals (Throne & Resnick, 1983; Fuselier et 
al., 1998). 
The high molecular weight substances includes glycosaminoglycans (710,000 
Dalions), acid peptides, RNA-like substances, acid glycoproteins (17,000 Daltons), 
nephrocalcin (NC) (14,000 Daltons), Tamm-Horsfall glycoprotein (THP) (80,000 
Daltons), glycoproteins or protoglycoproteins (Rose & Sulaiman, 1984; Thorne & 
Resnick, 1983; Asplin et al., 1991). There are several publications reported and 
suggested that these high molecular weight urinary components are strong inhibitors of 
• 
calcium oxalate crystal growth and their aggregation (Nakagawa et al., 1983; Nishio et 
al., 1985; Koide eta!., 1990; Hess, 1992; Chang et al., 2001a). It is also reported that 
the inhibitory activity of an inhibitor on crystal aggregation depends on the urinary pH 
and its ionic strength (IS). At high pH and low IS, THP is a powerful inhibitor of crystal 
aggregation and in contrary, it acts as promoter of calcium oxalate crystal aggregation at 
low pH and high IS (Hess, 1992). Chen et al. (2001) reported that THP showed 
uncertain inhibitory action on the crystallization of calcium oxalate monohydrate. This 
inhibitory action was partly related to sialic acid. 
The interesting role of glycosaminoglycans (GAGS) in calcium stone 
crystallization leading to the identification of a number of GAGS, which includes 
chondroitin sulphate, hyluronic acid, dermatan sulphate, heparin and heparan sulphate 
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(Nicolla, 1963; Goldberg & Cotlier, 1972; Robertson et al., 1973). Their mechanism of 
action are generally considered to be a result of adsorption of highly charged 
polysaccharide to crystal nidus and the surface of the growing crystal, thus retarding 
nucleation and growth (Sallis, 1987). 
Recenltly, Webber et al. (2002) purified urinary prothrombin fragment 1 
(UPTF1) and Hoyer et al. (2001) isolated osteopontin from human urine [uropontin 
(uOPN)], both exhibited potent inhibitory activity on calcium oxalate crystallization. 
Laube et al. (2001) reported that hippuric acid (HA) is a physiological component of 
human urine showed inhibitory activity on calcium oxalate growth and considerably 
enhances the calcium oxalate solubility in artificial urine. They concluded that HA was 
a major modifier of calcium oxalate formation. 
2.1.5 CHEMICAL INHIBITORS 
There are some chemical compounds found to have markedly inhibitory effects 
• 
on growth, nucleation or aggregation of calcium oxalate crystals such as allopurinol [4], 
methylene blue [5] and EDTA [6] as shown in Figure 2.2. Some :::re clinically useful 
compounds, such as sodium cellulose phosphate, disodium and dipotassium phosphates 
(Lepage & Tawashi, 1982; Tanagho & McAninch, 1988). 
Allopurinol is beneficial in prevention of calcium oxalate or uric acid stone 
(Charles & Pak, 1981; Emmerson, 1993). Methylene blue has been suggested as 
urolithiatic inhibitor, was found to be effective in the treatment of ne\v stone formation 
in patients with calcium oxalate renal calculi (Boyce et al., 1967; Ahmed & Tawashi. 
1978), but it gives adverse effect on uric acid calculi (Ismail et al., 1985). 
Ethylenediaminetetraacetic acid (EDTA), a chelating agent has also been used in a 
number of patients to dissolve the calcium containing calculi. However dissolution 
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often required thousands of irrigation, and a long hospitalization required to keep this 
treatment from achieving clinical popularity (Timmennann & Kallistrators, 1966). 
Oosterlinck et al. ( 1992) reported that dipotassium ethylenediaminetetraacetic acid is 
toxic to urothelium. The clinical use of calcium ligands is therefore unsafe. 
Figure 2.2: 
[1] Urea 
NL ~--~~)~ 
N ~ 
H 
[ 4] Allopurinol 
[2] Citrate 
o· o 
I I 
HO-P-P-0 
II II 
0 0 
[3] Pyrophosphate 
[5] Methylene blue 
·ooc-cH2, /CH2-coo 
N -CH2-CHr N, 
·ooC-CH2/ CHz-COO 
[6] EDTA 
Structural formula of low molecular weight urinary inhibitors (urea, 
citrate and pyrophosphate) and chemical inhibitors (allopurinol, 
methylene blue and EDTA). 
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2.1.6 NATURAL INHIBITORS FROM PLANTS (HERBAL MEDICINE) 
Herbal medicines rarely have significant side effects when used appropriately 
and at suggested doses. Occasionally, an herb at the prescribed dose causes stomach 
upset or headache. This may reflect the purity of the preparation or added ingredients, 
such as synthetic binders or fillers (Standard of Asean Herbal Medicine, 1993). For this 
reason, it is recommended that only high-quality products be used. Some plants 
traditionally found acceptable in treating diseases in the human body system in 
conditions related to kidney disorders are listed in Table 2.1. 
19 
Table 2.1: Plants used for kidney stone and related disPases 
Plant name Family Constituent Reference 
Blumea balsamifera Compositae Flavonoids, Burkill & Haniff, 
DC phytosterols, 1930; Burkill, 1966; 
(Capa) hydrocarbons Zhari et al., 1999 
Zea mays L (Corn Gramineae Flavones, saponins, Perry, 1985 
silk) tannin, minerals, Seno, 1988 
(Benang sari) phenolic acid 
Orthosiphon Labiatae Flavonoids, Burkill, 1966 
stamineus terpenoids, 
(Misai kuching) phytosterols, 
phenolic acid 
Ortlwsiphon Labiatae Fiavonoids, minerals Perry, 1985 
grandiflorus Seno, 1988 
(Kumis kuching) 
Sonchus arvensis (L) Compositae Flavonoids, ceryl Perry, 1985 
(Tempuyung) alcohol, choline Seno, 1988 
Raphanus sativus Cruciferae Flavonoids, Capta, 1987 
• (Lobak putih) carbohydrate, amino 
acids 
Shima noronhae Lauraceae Saponin and tannin Perry, 1985 
(Huru batu) 
Malpighia coccigera Malpighiaceae Flavonoids, Burkill, 1966 
(Teh hutan) triterpene, 
phytosterol 
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2.1.7 CRYSTALLIZ.ATION NHIBffiON STUDIES 
Stone formation is a biological process that involves a physicochemical element, 
crystallization. Two major aspects of crystallization are a thermodynamic one which 
includes supersaturation leading to nucleation, and a kinetic one which comprises the 
rate of nucleation, crystal growth and crystal agglomeration respectively (Kok et al., 
l990b). 
Baumann (1990) reported that chelators, inhibitors and promoters cou!d disturb 
the crystalliz:'tion process. In principle chelators trap the free ions and form soluble 
complex. Low molecular weight substances, such as magnesium, citrate, act as chelators 
as well inhibitors of growth and nucleation, are supposed to block growth sites on 
crystal niduses, on preformed crystal and also on some promoters. 
Macromolecules substances can convert an inhibitor to a promoter by 
polymerization (Embon et al., 1990) or immobilization on crystal surface (Hess, 1992). 
In this situation, they probably bind with a series of calcium ions, in a constellation that 
is ideal of epitaxy growth of calcium oxalate or calcium phosphate (Baumann, 1990). It 
seems that more than one factor are always involved in the formation and prevention of 
stone nucleus (King, 1967). 
Crystallization inhibition is a phenomena that clearly affects crystal growth and 
aggregation and related to the adsorption of a particular substance on the crystal surface. 
A number of methods on calcium oxalate crystallization inhibition studies have been 
published using inhibitors either in urine, from patients with urolithiasis or with normal 
subjects. It appears to be of fundamental importance to get information on the inhibiting 
properties of the urine. 
A !lumber of methods have been used for crystallization inhibition studies such 
as U-tube and polarized light (Bisaillon & Tawashi 1976), coulter counter technique 
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(f 1med L. Tawashi 1978), mixed suspension mixed product removal (Drach et al., 
1980), titrimetric method (Baumann & Wacker 1980), radioactivity technique (Tiselius 
& Pomander 1981), photometry technique (Schneider et al. 1983), vertical light path 
photometry technique (Achilles, 1985), nephelometry and optical microscopy technique 
(Grases et al. 1988), in vitro calcium oxalate crystallization system using [45Ca]calcium 
chloride (Atmani & Khan 1995), scanning electron microscopy and molecular modeling 
(Wierzbicki et al. 1995) turbidimetric method (Hennequin et al. 1997), 
immunofluorescence photomicrography coupled with scanning electron microscopy 
(Y amate et al. 1998), atomic force microscopy (Shirane et al. 1999) and 
spectrophotometric time-course measurements of optical density (Hess et al. 2000). 
All of the above methods measured the inhibitory activity of an inhibitor on a 
group of crystals. None of the above methods measures the inhibition activity on 
individual crystal formed. It is therefore necessary to develop a simple but accurate 
standardized method for estimating the inhibitory activity on individual crystals and 
• 
direct measurements of calcium oxalate crystal growth. 
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r 2.2 FLAVONOIDS 
2.2.1 GENERAL STRUCTURE AND MAJOR CLASSIFICATIONS 
Flavonoids are an ubiquitous group of polyphenolic substances, which are 
present in most plants, concentrating in leaves, seeds, fruit skin or peel, bark, and 
flowers (Herrmann, 1976, 1993; White & Xing, 1997). They are characterized by 
carbon skeleton C6-CyC6 [7] as shown in Figure 2.3. The basic structure of these 
compounds consists of two aromatic rings linked by a three carbon aliphatic· chain, 
which normally has been condensed to form a pyran or, less commonly a furan ring 
(Hollman et al., 1996). 
There is un array of substitution patterns on A, B, and C rings, as well as 
differences in where the B ring is bonded to the C ring, providing possibility fer the 
existence of numerous flavonoids, differing in their biological characteristics and 
chemical structures (Middleton & Kandaswami, 1994). Examples of different flavonoid 
• 
families are isoflavones [8], flavones [9], flavcnols [10], flavanones [11], 
dihydroflavonols [12] and anthocyanidins [13] (Figure 2.3). 
As with other flavonoids, the most frequently found flavonols and flavones are 
those with B-ring hydroxylation in the C-3' and 4' positions (Herrmann, 1976). 
Flavones Jack the hydroxyl group at C-3 in the middle ring that characterizes the 
flavonols. Quercetin and kaempferol are typical flavonols, the corresponding flavones 
being luteolin and epigenin respectively. Approximately 90% of the flavonoids in plants 
occur as glycosides (Macheix et al., 1990). The preferred binding site for the sugar 
residues is C-3 and Jess, frequently, in the A-ring at the C-7 position (Herrmann, 1976). 
The sugar free part of the flavonoid molecule is called the aglycone. 
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5 4 
0 0~ 
A OH 
0 
[ 10] Flavonol 
0 
[8] Isoflavone 
0 
[9] Flavone 
0 
[ 11] Flavanone 
[12] Dihydroflavonol [13] Anthocyanidin 
Figure 2.3: Structures of some flavonoid families. 
24 
